Bio-techne is a Top S&P 500 Stock. Germany's Merck is Paying a 24% Premium for the Company.

Dow Jones

Jun 26

Shares of Bio-Techne surged Thursday after Germany's Merck KGaA announced it agreed to purchase the company for $11.3 billion.

Bio-Techne stock jumped 20% to $70.55 on Thursday, placing it near the top of the S&P 500 for the trading session and set to log its best daily percentage gain since May 1, 2003, according to Dow Jones Market Data.

Merck KGaA plans to acquire Bio-Techne for $73 a share, according to the media release, representing a 24% premium based on the stock's closing price from Wednesday. The deal is expected to close later this year or early in 2027.

Merck said the acquisition of Bio-Techne will strengthen its presence in the life sciences market. Bio-Techne provides analytical technologies and life science tools used by researchers and drug manufacturers.

"Building on our strong track record in the life science business, this transaction strengthens our presence in some of the most exciting and fastest-growing areas of the life sciences," said Jean-Charles Wirth, a member of the executive board of Merck KGaA, in the media release.

Write to Kit Norton at kit.norton@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

June 25, 2026 15:12 ET (19:12 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2646025388"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2646025388\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2646025388?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-26 03:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2646025388","market":"sg","top_or_hot":-1,"title":"Bio-techne is a Top S&P 500 Stock. Germany's Merck is Paying a 24% Premium for the Company.","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Shares of Bio-Techne surged Thursday after Germany's <a href=\"https://laohu8.com/S/MKGAF\">Merck KGaA</a> announced it agreed to purchase the company for $11.3 billion. \n</p>\n<p>\n  Bio-Techne stock jumped 20% to $70.55 on Thursday, placing it near the top of the S&amp;P 500 for the trading session and set to log its best daily percentage gain since May 1, 2003, according to Dow Jones Market Data. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/MKKGY\">Merck KGaA</a> plans to acquire Bio-Techne for $73 a share, according to the media release, representing a 24% premium based on the stock's closing price from Wednesday. The deal is expected to close later this year or early in 2027. \n</p>\n<p>\n  Merck said the acquisition of Bio-Techne will strengthen its presence in the life sciences market. Bio-Techne provides analytical technologies and life science tools used by researchers and drug manufacturers. \n</p>\n<p>\n  \"Building on our strong track record in the life science business, this transaction strengthens our presence in some of the most exciting and fastest-growing areas of the life sciences,\" said Jean-Charles Wirth, a member of the executive board of Merck KGaA, in the media release. \n</p>\n<p>\n  Write to Kit Norton at kit.norton@barrons.com \n</p>\n<p>\n   This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 25, 2026 15:12 ET (19:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bio-techne is a Top S&P 500 Stock. Germany's Merck is Paying a 24% Premium for the Company.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBio-techne is a Top S&P 500 Stock. Germany's Merck is Paying a 24% Premium for the Company.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-26 03:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Shares of Bio-Techne surged Thursday after Germany's <a href=\"https://laohu8.com/S/MKGAF\">Merck KGaA</a> announced it agreed to purchase the company for $11.3 billion. \n</p>\n<p>\n  Bio-Techne stock jumped 20% to $70.55 on Thursday, placing it near the top of the S&amp;P 500 for the trading session and set to log its best daily percentage gain since May 1, 2003, according to Dow Jones Market Data. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/MKKGY\">Merck KGaA</a> plans to acquire Bio-Techne for $73 a share, according to the media release, representing a 24% premium based on the stock's closing price from Wednesday. The deal is expected to close later this year or early in 2027. \n</p>\n<p>\n  Merck said the acquisition of Bio-Techne will strengthen its presence in the life sciences market. Bio-Techne provides analytical technologies and life science tools used by researchers and drug manufacturers. \n</p>\n<p>\n  \"Building on our strong track record in the life science business, this transaction strengthens our presence in some of the most exciting and fastest-growing areas of the life sciences,\" said Jean-Charles Wirth, a member of the executive board of Merck KGaA, in the media release. \n</p>\n<p>\n  Write to Kit Norton at kit.norton@barrons.com \n</p>\n<p>\n   This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 25, 2026 15:12 ET (19:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2646025388","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2646025388","pubTimestamp":1782414720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Bio-Techne surged Thursday after Germany's Merck KGaA announced it agreed to purchase the company for $11.3 billion.Bio-Techne stock jumped 20% to $70.55 on Thursday, placing it near the top","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","MKKGY":"Merck KGaA","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","TECH":"Bio-Techne","BK4585":"ETF&股票定投概念","IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D","BK4588":"碎股","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","BK4121":"生命科学工具和服务"},"translate_title":"Bio-techne是标普500的顶级股票。德国默克公司为该公司支付了24%的溢价。","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TECH":1.97,"MKKGY":1.91},"content_text":"Shares of Bio-Techne surged Thursday after Germany's Merck KGaA announced it agreed to purchase the company for $11.3 billion. \n\n\n  Bio-Techne stock jumped 20% to $70.55 on Thursday, placing it near the top of the S&P 500 for the trading session and set to log its best daily percentage gain since May 1, 2003, according to Dow Jones Market Data. \n\n\nMerck KGaA plans to acquire Bio-Techne for $73 a share, according to the media release, representing a 24% premium based on the stock's closing price from Wednesday. The deal is expected to close later this year or early in 2027. \n\n\n  Merck said the acquisition of Bio-Techne will strengthen its presence in the life sciences market. Bio-Techne provides analytical technologies and life science tools used by researchers and drug manufacturers. \n\n\n  \"Building on our strong track record in the life science business, this transaction strengthens our presence in some of the most exciting and fastest-growing areas of the life sciences,\" said Jean-Charles Wirth, a member of the executive board of Merck KGaA, in the media release. \n\n\n  Write to Kit Norton at kit.norton@barrons.com \n\n\n   This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 25, 2026 15:12 ET (19:12 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}